Skip to main content
. 2016 Jul 21;1(2):123–135. doi: 10.1002/btm2.10017

Table 1.

Highest fold‐changes in transfection priming hits at 5mM of NCC compounds

Compound Drug type Transfectiona Cell‐countb Hoechst‐intensityc Resazurin‐intensityd
Transfection fold‐increase Zolpidem tartrate GABA receptor modulator 3.05 0.52
Resveratrol Stilbenoid 3.04 0.55
Tropisetron hydrochloride Serotonin receptor antagonist 2.67 0.97 0.91 1.07
Tranilast Anti‐allergy 2.17 0.74 1.11 1.29
Lansoprazole Proton‐pump inhibitor 2.13 0.72 1.13 1.42
Nobiletin Flavonoid 2.08 0.61 1.23 1.21
Nitrazepam GABA receptor modulator 2.03 0.53
Enalaprilat Angiotensin‐converting‐enzyme inhibitor pro‐drug 2.00 0.55 1.35 1.51
Droperidol Dopamine receptor antagonist 1.95 0.52
Mestanolone Androgen hormone 1.93 0.61 1.26
Transfection fold‐decrease Epigallocatechin gallate Flavonoid 0.08 1.37 0.88
Ampiroxicam Nonsteroidal anti‐inflammatory drug 0.31 0.93 0.91 1.14
Nimodipine Calcium channel blocker 0.35 0.90
(−)‐Cotinine Nicotine metabolite 0.41 0.87 1.16
Ramipril Angiotensin‐converting‐enzyme inhibitor 0.42 0.98 0.92
Desloratadine Anti‐histamine 0.50 0.86 1.19
Crotamiton Anti‐itch 0.50 0.98 0.93
Guanidine Amino acid metabolite 0.52 0.93 1.12
Letrozole Estrogen synthesis inhibitor 0.52 1.00 0.87
Fluphenazine hydrochloride Dopamine receptor antagonist 0.53 0.85 1.08 1.17

Note. Empty values indicate nonsignificant fold‐change.

a

Transfection fold‐changes were calculated from duplicate averages of EGFP fluorescence, measured by EGFP cell‐count (image processing) or EGFP intensity (plate reader and image processing), relative to the same measurement averaged from the vehicle controls in each compound's respective plates. These measurements were normalized in two separate ways, total cell‐count (determined by Hoechst‐count), and transfected cell‐count (determined by EGFP‐count), for measurement of transfection per cell as well as transfection per transfected cell.

b

Cell‐count fold‐changes were calculated from duplicate averages of image processing measurements of Hoechst‐count relative to the average Hoechst‐count measurements of vehicle controls in each compound's respective plates. Cell‐count fold‐changes are shown for each hit presented as a general toxicity reference, not to imply significant increase or decrease.

c

Hoechst‐intensity fold changes were calculated from duplicate averages of plate reader or image processing measurements of Hoechst‐intensity normalized by total cell‐count (determined by Hoechst‐count), relative to the average Hoechst‐intensity measurements of vehicle controls in each compound's respective plates.

d

Resazurin‐intensity fold changes were calculated from duplicate averages of plate reader measurements of resazurin intensity normalized by cell‐count (determined by Hoechst‐count), relative to the average resazurin‐intensity measurements of vehicle controls in each compound's respective plates.